Cargando…

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia

Imatinib, which inhibits tyrosine kinase activity of Bcr-Abl protein, is a standard form of treatment for chronic myeloid leukemia (CML). Through its immunomodulatory effect it affects T cell function in a number of ways. It inhibits antigen-induced T cell activation and proliferation. Antigen-speci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chandra, Abhilash, Rao, Namrata, Malhotra, Kiran Preet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Nefrologia 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657051/ https://www.ncbi.nlm.nih.gov/pubmed/32353102 http://dx.doi.org/10.1590/2175-8239-JBN-2019-0123

Ejemplares similares

Impact of COVID 19 pandemic on patients requiring renal biopsy
por: Chandra, Abhilash, et al.
Publicado: (2022)

Discontinuation of Imatinib Mesylate could Improve Renal Impairment in Chronic Myeloid Leukemia
por: Malkan, Umit Y., et al.
Publicado: (2018)

Successful kidney transplantation in a patient with pre‐existing chronic myeloid leukemia treated with imatinib
por: Thiem, Ursula, et al.
Publicado: (2020)

B-Cell Chronic Lymphocytic Leukemia with 11q22.3 Rearrangement in Patient with Chronic Myeloid Leukemia Treated with Imatinib
por: Lewandowski, Krzysztof, et al.
Publicado: (2016)

Imatinib-Induced Tremor in a Patient with Chronic Myeloid Leukemia in Chronic Phase
por: Obeidat, Khaldun, et al.
Publicado: (2019)

An uneventful pregnancy and delivery, in a case with chronic myeloid leukemia on imatinib
por: Martin, Jovita, et al.
Publicado: (2011)

Kaposi’s sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy
por: D’Addona, Matteo, et al.
Publicado: (2022)

Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia
por: Nakamura, Yuichi, et al.
Publicado: (2022)

A case of subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib mesylate
por: Kim, Min Sik, et al.
Publicado: (2010)

Successful Peripheral Blood Stem Cells Collection in Imatinib Pretreated and Nilotinib-Treated Chronic Myeloid Leukemia Patient
por: Vokurka, Samuel, et al.
Publicado: (2010)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis
por: Go, Seong Woo, et al.
Publicado: (2013)

Imatinib-induced Extensive Hyperpigmentation in a Case of Chronic Myeloid Leukemia
por: Balasubramanian, Pradeep, et al.
Publicado: (2015)

Follicular Dendritic Cell Sarcoma of Lymph Node: A report of a Patient with Chronic Myeloid Leukemia Treated with Imatinib
por: Sharma, Nisha, et al.
Publicado: (2015)

Pregnancy and Accelerated Phase of Myeloid Chronic Leukemia Treated with Imatinib: A Case Report from a Developing Country
por: Ngolet, Lydie Ocini, et al.
Publicado: (2016)

Imatinib-induced gastric antral vascular ectasia in a patient with chronic myeloid leukemia
por: Alshehry, Nawal F, et al.
Publicado: (2014)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

A Unique Case of Renal Infiltration by Lymphoplasmacytic Lymphoma with Cast Nephropathy
por: Malhotra, Kiran P., et al.
Publicado: (2020)

Chronic Myeloid Leukemia Preceded by Tuberculosis
por: Al-Qudah, Bara M., et al.
Publicado: (2020)

Imatinib Treatment of Chronic Myeloid Leukemia Reveals a Preexisting CALR-mutated Essential Thrombocythemia
por: Blouet, Anaïse, et al.
Publicado: (2018)

The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia
por: Zhu, Yu, et al.
Publicado: (2016)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
por: Martins, Darlize Hübner, et al.
Publicado: (2011)

Targeted treatment of chronic myeloid leukemia: role of imatinib
por: Tamascar, Ila, et al.
Publicado: (2009)

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?
por: Trela, Ewelina, et al.
Publicado: (2014)

Successful determination of imatinib re‐administration dosage by therapeutic drug monitoring in a case of chronic myeloid leukemia initiating dialysis for acute renal dysfunction
por: Nakahara, Ryosuke, et al.
Publicado: (2021)

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
por: Uz, B., et al.
Publicado: (2011)

Imatinib-induced decompensated heart failure in an elderly patient with chronic myeloid leukemia: case report and literature review
por: Ran, Hai-Hong, et al.
Publicado: (2012)

Late Emergence of an Imatinib-Resistant ABL1 Kinase Domain Mutation in a Patient with Chronic Myeloid Leukemia
por: Crampe, Mireille, et al.
Publicado: (2017)

Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag
por: Autore, Francesco, et al.
Publicado: (2021)

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
por: Abou Dalle, Iman, et al.
Publicado: (2019)

Chronic myeloid leukemia developing in treated acute promyelocytic leukemia
por: Abbasi, Abdul Muqtadir, et al.
Publicado: (2022)

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
por: Shea, Lauren K., et al.
Publicado: (2017)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
por: Linga, Vijay Gandhi, et al.
Publicado: (2014)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016)

Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia
por: Kavanagh, Simon, et al.
Publicado: (2018)

Uncontrolled neovascular glaucoma – an alarming manifestation of chronic myeloid leukemia on imatinib therapy – a case report and review of literature
por: Roop, Prakhyat, et al.
Publicado: (2019)

Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia
por: Shah, Shilpan, et al.
Publicado: (2014)

Leptin modification in chronic myeloid leukemia patients treated with imatinib: An emerging effect of targeted therapy.()
por: Mariani, Stefania, et al.
Publicado: (2013)

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia
por: Gugliotta, Gabriele, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ebl9gj5fs8kjflho36iu13pq2t